China approves inactivated COVID-19 vaccines for clinical trials
BEIJING, April 14 (Xinhua) -- China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus Tuesday.
The two vaccine candidates are developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd, a company based in Beijing. Clinical trials of the two vaccines have started.
[caption id="" align="alignnone" width="900"]